2023
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life
Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.Peer-Reviewed Original ResearchLethal prostate cancerSociodemographic factorsAdvanced CaPAdvanced diseaseYounger patientsProstate cancerHigher oddsAdvanced stageProstate-specific antigen (PSA) screeningCharacteristics of patientsNational Cancer DatabaseRetrospective cohort studySubset of patientsPatient sociodemographic factorsMultivariable logistic regressionPatients' health insuranceHighest income quartileCohort studyAdvanced cancerAntigen screeningMean ageInsurance statusCancer DatabaseCaP screeningSociodemographic disparitiesSaudi consensus guidance for the management of inflammatory bowel disease during pregnancy.
Azzam N, Almutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B, Mosli M. Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy. Saudi Journal Of Gastroenterology 2023, 30 PMID: 38099556, PMCID: PMC11379253, DOI: 10.4103/sjg.sjg_318_23.Peer-Reviewed Original ResearchInflammatory bowel diseaseManagement of IBDPregnant womenBowel diseaseClear evidence-based recommendationsSubset of patientsClinical care pathwayExpert opinion recommendationsOptimal patient managementEvidence-based recommendationsMultidisciplinary working groupCare pathwayClinical pharmacologyPatient managementPatient basisConsensus guidanceMultidisciplinary teamSaudi MinistryWomenPatientsDiseaseConcise guidelinesWorking GroupLiterature reviewManagementAnatomic patterns in claudicants who fail supervised exercise therapy
Breen T, McGinigle K, Strosberg D, Dardik A, Altin S. Anatomic patterns in claudicants who fail supervised exercise therapy. Journal Of Vascular Surgery 2023, 79: 679-684.e1. PMID: 37984757, DOI: 10.1016/j.jvs.2023.11.020.Peer-Reviewed Original ResearchCritical limb-threatening ischemiaSupervised exercise therapyPeripheral arterial diseaseIntermittent claudicationCFA diseaseExercise therapyArterial diseaseAnatomic patternsCommon femoral artery diseaseFemoral artery diseaseAnkle-brachial indexLimb-threatening ischemiaSubset of patientsVeterans Health AdministrationPersistent symptomsProgressive diseaseProgressive symptomsArtery diseaseDisease locationPatientsWest HavenHealth AdministrationMultivariate analysisRevascularizationDiseaseDeucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Sofen H, Strober B, Imafuku S, Paul C, Gooderham M, Spelman L, Seo S, Passeron T, Kisa R, Berger V, Vritzali E, Hoyt K, Colombo M, Banerjee S, Augustin M, Stein Gold L, Alexis A, Thaçi D, Blauvelt A, Lebwohl M. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal Of Cutaneous Medicine 2023, 7: s241. DOI: 10.25251/skin.7.supp.241.Peer-Reviewed Original ResearchPASI 75 respondersSevere plaque psoriasisPASI 75PASI 90Week 148Plaque psoriasisWeek 52Week 16Week 24Parent trialClinical efficacyDay 1Response rateLong-term extension trialsNew safety signalsPhase 3 trialSubset of patientsMaintenance of responseLong-term efficacyLong-term effectivenessNonresponder imputationOral placeboPsoriasis AreaExtension trialSafety signalsComparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT
Katoch D, Nallagatla V, Krishnamurti L. Comparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT. Blood 2023, 142: 3873. DOI: 10.1182/blood-2023-190977.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseComplications of SCDGraft failureOverall survivalAsymptomatic patientsAvascular necrosisSCD patientsDonor typeChronic GVHDCell transplantationCell diseaseOutcomes of HCTPost-transplant lymphoproliferative disorderSubstantial short-term morbidityCommon graft sourceExperienced graft failureHCT comorbidity indexAcute chest syndromeHLA-identical donorShort-term morbidityLong-term sequelaePotential curative optionSubset of patientsOrgan-specific complicationsCost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease. Blood 2023, 142: 3698. DOI: 10.1182/blood-2023-188018.Peer-Reviewed Original ResearchSevere von Willebrand diseaseLong-term prophylaxisIncremental net monetary benefitVon Willebrand diseasePlasma-derived von Willebrand factorIncremental cost-effectiveness ratioNet monetary benefitVon Willebrand factorProbabilistic sensitivity analysesDeterministic sensitivity analysesSevere haemophiliaWillebrand factorRecombinant von Willebrand factorWillebrand diseasePhase 3 clinical trialsHealth resource utilizationFactor replacement therapyFrequency of infusionsSubset of patientsCost of prophylaxisType 3 von Willebrand diseaseFactor replacement productsSimilar significant improvementsSevere phenotypeNon-significant reductionDIAGNOSING THE UNCOMMON: BULLOUS PEMPHIGOID PRESENTING AS ECZEMATOUS DERMATITIS AND SEVERE PRURITIS
You L, Kwah J, Cohen J, Wong K. DIAGNOSING THE UNCOMMON: BULLOUS PEMPHIGOID PRESENTING AS ECZEMATOUS DERMATITIS AND SEVERE PRURITIS. Annals Of Allergy Asthma & Immunology 2023, 131: s189-s190. DOI: 10.1016/j.anai.2023.08.584.Peer-Reviewed Original ResearchAtopic dermatitisBullous pemphigoidSevere pruritusVariable clinical presentationSkin lesionsEczematous dermatitisCases of BPMonths of therapyHistory of asthmaSubset of patientsElevated IgG antibodiesSevere pruritisTense bullaeTopical corticosteroidsAllergic rhinitisPersistent pruritusAppropriate patientsInitial presentationScaly rashClinical presentationRare entityFinal diagnosisIgG antibodiesRare conditionCommon conditionMechanical Thrombectomy for High-Risk Pulmonary Embolism: Insights From the US Cohort of the FLASH Registry
Horowitz J, Jaber W, Stegman B, Rosenberg M, Fanola C, Bhat A, Gondi S, Castle J, Ahmed M, Brown M, Amin R, Bisharat M, Butros P, DuCoffe A, Savin M, Pollak J, Weinberg M, Brancheau D, Toma C, Investigators F. Mechanical Thrombectomy for High-Risk Pulmonary Embolism: Insights From the US Cohort of the FLASH Registry. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 3: 101124. PMID: 39131977, PMCID: PMC11307390, DOI: 10.1016/j.jscai.2023.101124.Peer-Reviewed Original ResearchHigh-risk pulmonary embolismMajor adverse eventsPulmonary embolismMechanical thrombectomyAdverse eventsUS cohortProcedure-related adverse eventsAcute mortalityDepressed cardiac indexDevice-related mortalityRisk pulmonary embolismSubset of patientsSystolic blood pressureFurther prospective dataMin/m2Intensive care unitElevated lactate levelsComers registryFlowTriever SystemMajor bleedingCardiac indexCardiology guidelinesAcute outcomesBlood pressureCare unitMachine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis
Murphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.Peer-Reviewed Original ResearchCo-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.Peer-Reviewed Original ResearchProgression-free survivalEGFR-mutant NSCLCTP53 mutationsOverall survivalClinical outcomesEGFR-TKIInferior outcomesWorse outcomesYale cohortMetastatic EGFR-mutant NSCLCShorter progression-free survivalEGFR-mutant lung cancerTyrosine kinase inhibitor therapyFirst-line TKIYale Cancer CenterSecond-line therapyInferior clinical outcomesSubset of patientsKinase inhibitor therapyAdditional therapeutic interventionsAggressive disease phenotypeCo-occurring alterationsTumor suppressor gene alterationsTumor genomic profilingMultiple tumor suppressor genesMulti-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis
Morris M, Jain A, Sun B, Kurbatov V, Muca E, Zeng Z, Jin Y, Roper J, Lu J, Paty P, Johnson C, Khan S. Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis. Cancer Letters 2023, 574: 216384. PMID: 37716465, PMCID: PMC10620771, DOI: 10.1016/j.canlet.2023.216384.Peer-Reviewed Original ResearchConceptsLiver metastasesColon cancer liver metastasisCancer liver metastasesSided colon cancerSubset of patientsGrowth factor betaMulti-omics analysisFatty acid oxidationMetastatic diseaseInferior survivalClinical differencesClinical behaviorUntargeted metabolomics analysisTumor behaviorColon cancerBile acidsTumor cell metabolismFactor betaPatientsMetastasisPI3K-AktReactive oxygen speciesMEK-ERKLiquid chromatography-mass spectrometryRCCSome Offset Restoration Options Can Paradoxically Lead to Decreased Range of Motion in Primary Total Hip Arthroplasty: A 3-Dimensional Computer Simulation Study
Pour A, Donnelley C, Tung W, Tommasini S, Wiznia D. Some Offset Restoration Options Can Paradoxically Lead to Decreased Range of Motion in Primary Total Hip Arthroplasty: A 3-Dimensional Computer Simulation Study. The Journal Of Arthroplasty 2023, 39: 514-519.e3. PMID: 37625464, PMCID: PMC10843541, DOI: 10.1016/j.arth.2023.08.057.Peer-Reviewed Original ResearchConceptsTotal hip arthroplastyRange of motionPrimary total hip arthroplastyHip flexionHip arthroplastyParadoxical increaseHigh-offset stemsRobotic arm-assisted total hip arthroplastyGroup of patientsSubset of patientsSagittal pelvic tiltVarus neckMaximum internal rotationPelvic tiltOptimizing outcomesImplant design featuresDecreased rangeHip extensionExternal rotationImplant choiceProsthetic headMaximum external rotationFlexionImpingement riskLiner useReduction of Nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43-related neurodegeneration
Tejwani L, Jung Y, Kokubu H, Sowmithra S, Ni L, Lee C, Sanders B, Lee P, Xiang Y, Luttik K, Soriano A, Yoon J, Park J, Ro H, Ju H, Liao C, Tieze S, Rigo F, Jafar-Nejad P, Lim J. Reduction of Nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43-related neurodegeneration. Journal Of Clinical Investigation 2023, 133: e138207. PMID: 37384409, PMCID: PMC10425213, DOI: 10.1172/jci138207.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisTDP-43-related neurodegenerationNeurodegenerative disordersTransactive response DNA-binding protein 43Sporadic amyotrophic lateral sclerosisDNA-binding protein 43Subset of patientsTDP-43 speciesTDP-43 inclusionsDistinct mouse modelsTDP-43 proteinopathyFamilial amyotrophic lateral sclerosisNemo-like kinaseMultiple neurodegenerative disordersAutophagy/lysosome pathwayTDP-43-positive aggregatesALS patientsALS casesSporadic ALSPharmacological reductionProtein 43Lateral sclerosisMouse modelParkinson's diseaseTDP-43A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1
Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Couselo E, Rodríguez-Abreu D, Boni V, Schuchter L, Gonzalez-Cao M, Arance A, Wei W, Ganti A, Hauke R, Berrocal A, Iannotti N, Hsu F, Kluger H. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical Cancer Research 2023, 30: 74-81. PMID: 37535056, PMCID: PMC10767304, DOI: 10.1158/1078-0432.ccr-23-0475.Peer-Reviewed Original ResearchConceptsObjective response ratePhase II trialAdverse eventsPartial responseDisease progressionII trialGrade 3 adverse eventsAnti PD-1CD40 agonist antibodyElevated liver functionTreatment-related SAEsCommon adverse eventsActivation of CD40Subset of patientsFavorable safety profileAntigen presenting cellsStable diseaseMedian durationAdvanced melanomaAdditional patientsLiver functionSafety profileMetastatic melanomaPreclinical dataPresenting cellsBiomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Finocchiaro G, Ahn M, Luft A, Landers G, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst R. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nature Medicine 2023, 29: 1718-1727. PMID: 37429923, DOI: 10.1038/s41591-023-02385-6.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerObjective response rateAdvanced non-small cell lung cancerCell lung cancerSafety profileCombination therapyLung cancerInvestigator-assessed objective response rateRandomized phase 2 studySolid Tumors version 1.1T-cell-inflamed gene expression profileGroup IIIBiomarker-defined subgroupsFirst-line pembrolizumabPhase 2 studyProgression-free survivalResponse Evaluation CriteriaSubset of patientsHeterogenous tumor microenvironmentData cutoffOverall survivalSecondary outcomesPrimary outcomeTreatment armsTMB assessmentCharacteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
Silva-Rodríguez J, Labrador-Espinosa M, Moscoso A, Schöll M, Mir P, Grothe M, Weiner M, Aisen P, Petersen R, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Perrin R, Shaw L, Khachaturian Z, Carrillo M, Potter W, Barnes L, Bernard M, González H, Ho C, Hsiao J, Jackson J, Masliah E, Masterman D, Okonkwo O, Perrin R, Ryan L, Silverberg N, Fleisher A, Weiner M, Sacrey D, Fockler J, Conti C, Veitch D, Neuhaus J, Jin C, Nosheny R, Ashford M, Flenniken D, Kormos A, Green R, Montine T, Conti C, Petersen R, Aisen P, Rafii M, Raman R, Jimenez G, Donohue M, Gessert D, Salazar J, Zimmerman C, Cabrera Y, Walter S, Miller G, Coker G, Clanton T, Hergesheimer L, Smith S, Adegoke O, Mahboubi P, Moore S, Pizzola J, Shaffer E, Sloan B, Beckett L, Harvey D, Donohue M, Jack C, Forghanian-Arani A, Borowski B, Ward C, Schwarz C, Jones D, Gunter J, Kantarci K, Senjem M, Vemuri P, Reid R, Fox N, Malone I, Thompson P, Thomopoulos S, Nir T, Jahanshad N, DeCarli C, Knaack A, Fletcher E, Harvey D, Tosun-Turgut D, Chen S, Choe M, Crawford K, Yushkevich P, Das S, Jagust W, Koeppe R, Reiman E, Chen K, Mathis C, Landau S, Morris J, Perrin R, Cairns N, Householder E, Franklin E, Bernhardt H, Taylor-Reinwald L, Shaw L, Trojanowki J, Korecka M, Figurski M, Toga A, Crawford K, Saykin A, Nho K, Risacher S, Apostolova L, Shen L, Foroud T, Nudelman K, Faber K, Wilmes K, Weiner M, Thal L, Khachaturian Z, Hsiao J, Schneider L, Silbert L, Pawluczyk S, Lind B, Becerra M, Crissey R, Teodoro L, Kaye J, Dagerman K, Carter R, Spann B, Dolen S, Quinn J, Brewer J, Vanderswag H, Fleisher A, Ziolkowski J, Heidebrink J, Zbizek-Nulph L, Lord J, Zbizek-Nulph L, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Villanueva-Meyer J, Pavlik V, Pacini N, Lamb A, Kass J, Doody R, Shibley V, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Mintz A, Ances B, Morris J, Winkfield D, Carroll M, Stobbs-Cucchi G, Oliver A, Creech M, Mintun M, Schneider S, Geldmacher D, Love M, Griffith R, Clark D, Brockington J, Marson D, Grossman H, Goldstein M, Greenberg J, Mitsis E, Shah R, Lamar M, Duara R, Greig-Custo M, Rodriguez R, Albert M, Onyike C, Farrington L, Rudow S, Brichko R, Kielb S, Smith A, Raj B, Fargher K, Sadowski M, Wisniewski T, Shulman M, Faustin A, Rao J, Castro K, Ulysse A, Chen S, Sheikh M, Singleton-Garvin J, Doraiswamy P, Petrella J, James O, Wong T, Borges-Neto S, Karlawish J, Wolk D, Vaishnavi S, Clark C, Arnold E, Smith C, Jicha G, Khouli R, Raslau F, Lopez O, Oakley M, Simpson D, Porsteinsson A, Martin K, Kowalski N, Keltz M, Goldstein B, Makino K, Ismail M, Brand C, Thai G, Pierce A, Yanez B, Sosa E, Witbracht M, Kelley B, Nguyen T, Womack K, Mathews D, Quiceno M, Levey A, Lah J, Hajjar I, Cellar J, Burns J, Swerdlow R, Brooks W, Silverman D, Kremen S, Apostolova L, Tingus K, Lu P, Bartzokis G, Woo E, Teng E, Graff-Radford N, Parfitt F, Poki-Walker K, Farlow M, Hake A, Matthews B, Brosch J, Herring S, van Dyck C, Mecca A, Good S, MacAvoy M, Carson R, Varma P, Chertkow H, Vaitekunis S, Hosein C, Black S, Stefanovic B, Heyn C, Hsiung G, Kim E, Mudge B, Sossi V, Feldman H, Assaly M, Finger E, Pasternak S, Rachinsky I, Kertesz A, Drost D, Rogers J, Grant I, Muse B, Rogalski E, Robson J, Mesulam M, Kerwin D, Wu C, Johnson N, Lipowski K, Weintraub S, Bonakdarpour B, Pomara N, Hernando R, Sarrael A, Rosen H, Miller B, Perry D, Turner R, Johnson K, Reynolds B, MCCann K, Poe J, Sperling R, Johnson K, Marshall G, Yesavage J, Taylor J, Chao S, Coleman J, White J, Lane B, Rosen A, Tinklenberg J, Belden C, Atri A, Spann B, Clark K, Zamrini E, Sabbagh M, Killiany R, Stern R, Mez J, Kowall N, Budson A, Obisesan T, Ntekim O, Wolday S, Khan J, Nwulia E, Nadarajah S, Lerner A, Ogrocki P, Tatsuoka C, Fatica P, Fletcher E, Maillard P, Olichney J, DeCarli C, Carmichael O, Bates V, Capote H, Rainka M, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Perrin A, Burke A, Scharre D, Kataki M, Tarawneh R, Kelley B, Hart D, Zimmerman E, Celmins D, Miller D, Ponto L, Smith K, Koleva H, Shim H, Nam K, Schultz S, Williamson J, Craft S, Cleveland J, Yang M, Sink K, Ott B, Drake J, Tremont G, Daiello L, Drake J, Sabbagh M, Ritter A, Bernick C, Munic D, Mintz A, O’Connelll A, Mintzer J, Wiliams A, Masdeu J, Shi J, Garcia A, Sabbagh M, Newhouse P, Potkin S, Salloway S, Malloy P, Correia S, Kittur S, Pearlson G, Blank K, Anderson K, Flashman L, Seltzer M, Hynes M, Santulli R, Relkin N, Chiang G, Lee A, Lin M, Ravdin L, Weiner M, Aisen P, Petersen R, Weiner M, Aisen P, Petersen R, Green R, Harvey D, Jack C, Jagust W, Morris J, Saykin A, Shaw L, Toga A, Trojanowki J, Neylan T, Grafman J, Green R, Montine T, Weiner M, Petersen R, Aisen P, Jimenez G, Donohue M, Gessert D, Salazar J, Zimmerman C, Walter S, Adegoke O, Mahboubi P, Hergesheimer L, Danowski S, Coker G, Clanton T, Pizzola J, Shaffer E, Nguyen-Barrera C, Neylan T, Hayes J, Finley S, Harvey D, Jack C, Bernstein M, Borowski B, Gunter J, Senjem M, Kantarci K, Ward C, Tosun-Turgut D, Chen S, Landau S, Koeppe R, Foster N, Reiman E, Chen K, Morris J, Perrin R, Franklin E, Shaw L, Trojanowki J, Korecka M, Figurski M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Faber K, Kim S, Nho K, Wilmes K, Schneider L, Pawluczyk S, Becerra M, Teodoro L, Dagerman K, Spann B, Brewer J, Vanderswag H, Fleisher A, Stern Y, Honig L, Mintz A, Shah R, Sood A, Blanchard K, Fleischman D, Arfanakis K, Duara R, Varon D, Greig M, Doraiswamy P, Petrella J, James O, Borges-Neto S, Wong T, Porsteinsson A, Goldstein B, Martin K, Thai G, Pierce A, Reist C, Yanez B, Sosa E, Witbracht M, Sadowsky C, Martinez W, Villena T, Rosen H, Perry D, Turner R, Johnson K, Reynolds B, MCCann K, Poe J, Sperling R, Johnson K, Marshall G, Belden C, Atri A, Spann B, Clark K, Zamrini E, Sabbagh M, Obisesan T, Ntekim O, Wolday S, Nwulia E, Nadarajah S, Johnson S, Asthana S, Carlsson C, Peskind E, Petrie E, Li G, Yesavage J, Taylor J, Chao S, Coleman J, White J, Lane B, Rosen A, Tinklenberg J, Lin M, Chiang G, Ravdin L, Relkin N, O’Connelll A, Mintzer J, Wiliams A, Mackin S, Aisen P, Raman R, Jimenez-Maggiora G, Donohue M, Gessert D, Salazar J, Zimmerman C, Walter S, Adegoke O, Mahboubi P, Mackin S, Weiner M, Aisen P, Raman R, Jack C, Landau S, Saykin A, Toga A, DeCarli C, Koeppe R, Green R, Drake E, Weiner M, Aisen P, Raman R, Donohue M, Mackin S, Nelson C, Bickford D, Butters M, Zmuda M, Jack C, Rochester C, Bernstein M, Borowski B, Gunter J, Senjem M, Kantarci K, Ward C, Reyes D, Koeppe R, Landau S, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Faber K, Nho K, Nudelman K, Mackin S, Rosen H, Nelson C, Bickford D, Au Y, Scherer K, Catalinotto D, Stark S, Ong E, Fernandez D, Butters M, Zmuda M, Lopez O, Oakley M, Simpson D. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology. Brain 2023 PMID: 37284793, DOI: 10.1093/brain/awad194.Peer-Reviewed Original ResearchLewy body pathologyFDG-PET patternsFDG-PET scansDisease dementiaAlzheimer's disease dementiaHypometabolism patternsDisease patientsDisease Neuroimaging InitiativeClinical diagnosisAMCI patientsADD patientsSubset of patientsSpecific clinical featuresFDG-PET imagingPresence of hallucinationsAlzheimer's disease patientsAlzheimer's disease biomarkersAmnestic mild cognitive impairmentDisease biomarkersMild cognitive impairmentAlzheimer's Disease Neuroimaging InitiativeGlucose hypometabolismClinical featuresLewy bodiesTau-PETPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinomaPathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.
Tripathi A, Tangen C, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. Journal Of Clinical Oncology 2023, 41: 4562-4562. DOI: 10.1200/jco.2023.41.16_suppl.4562.Peer-Reviewed Original ResearchProgression-free survivalPositive predictive valueCentral pathology reviewCentral reviewPathology reviewHistologic subtypeType 1PRCC subtypesAdvanced papillary renal cell carcinomaPathologic concordance rateLines of therapyPapillary renal cell carcinomaSubset of patientsType 2 tumorGreater clinical benefitRenal cell carcinomaLimited clinical valueType 2 diseaseExpert genitourinary pathologistsLocal reviewClassification of subtypesSunitinib armMET alterationsClinical outcomesClinical benefitManagement of Pathologic Node-Positive Prostate Cancer following Radical Prostatectomy
Hayden C, Rahman S, Lokeshwar S, Choksi A, Kim I. Management of Pathologic Node-Positive Prostate Cancer following Radical Prostatectomy. Current Oncology Reports 2023, 25: 729-734. PMID: 37071296, DOI: 10.1007/s11912-023-01420-6.Peer-Reviewed Original ResearchConceptsAdjuvant androgen deprivation therapyNode-positive prostate cancerStandard of careRadical prostatectomyRadiation therapyProstate cancerPathologic node-positive patientsAdjuvant radiation therapyAndrogen deprivation therapyNode-positive patientsSalvage radiation therapySubset of patientsRobust clinical trialsProstate cancer patientsRecent systematic reviewDeprivation therapyCause mortalityTreatment optionsCancer patientsClinical trialsPatientsControl groupSystematic reviewTherapyProstatectomyRemission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply